351
|
Gallais Sérézal I, Le Jeune S, Belenfant X, Bakir R, Fain O, Mekinian A, Gambier N, Mouthon L, Steichen O, Blanche P, Mourad JJ, Dhôte R. [Idiopathic retroperitoneal fibrosis: a multicentric retrospective study of 30 French cases and follow-up of the renal function]. Rev Med Interne 2013; 35:570-6. [PMID: 24314845 DOI: 10.1016/j.revmed.2013.11.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Revised: 09/23/2013] [Accepted: 11/02/2013] [Indexed: 12/11/2022]
Abstract
PURPOSE Idiopathic retroperitoneal fibrosis (IRF) is an inflammatory disorder, affecting the aorta and the surrounding vessels and tissues. The prognosis is mainly driven by the risks of chronic kidney disease and relapse. Our aim was to assess the prevalence of chronic kidney disease at follow-up. METHODS We retrospectively reviewed the medical records of patients diagnosed for IRF in Seine-Saint-Denis (France) between 1987 and 2011. We collected informations about presentation, radiologic findings and follow-up. Diagnosis of IRF was confirmed when all the following criteria were met: infiltration of the infrarenal aorta or iliac vessels, absence of aneurysmal dilation, lack of clinical suspicion of malignancy. RESULTS Thirty patients were identified, with a male/female ratio of 4.9. Mean age was 55±13 years old. The mean creatinine clearance was 66 mL/min/1.73 m(2) and the mean CRP was 45±36 mg/L. In 24 (80%) patients, the location of IRF was periaortic and periiliac. Eleven patients (37%) underwent a diagnostic biopsy, and 14 (47%) required an ureteral procedure. A mean follow-up of 63 months was available for 29 patients: 69% relapsed, 7 developed chronic renal disease (24%), and one died of urinary sepsis. Older age (P=0.023), diabetes (P=0.007), and initial renal insufficiency (P=0.05) were associated with a risk of chronic renal insufficiency. CONCLUSION The high frequency of relapses and chronic renal disease emphasizes the need of close follow-up in patients diagnosed with IRF.
Collapse
|
352
|
Defendi F, Charignon D, Ghannam A, Ponard D, Nicolie B, Fain O, Martin L, Drouet C. Intérêt de l’étude du métabolisme de la bradykinine (BK) pour la prise en charge des angioedèmes. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
353
|
Abisror N, Mekinian A, Lachassinne E, Nicaise-Roland P, De Pontual L, Chollet-Martin S, Boddaert N, Carbillon L, Fain O. Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome. Semin Arthritis Rheum 2013; 43:348-51. [DOI: 10.1016/j.semarthrit.2013.07.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2013] [Revised: 05/14/2013] [Accepted: 07/03/2013] [Indexed: 11/29/2022]
|
354
|
Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn J, Fenaux P, Fain O. Manifestations auto-immunes au cours de syndromes myélodysplasiques. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
355
|
Mekinian A, Costedoat-Chalumeau N, Masseau A, Emmanuelli V, Hachulla E, Botta A, Subtil D, Revaux A, Nicaise-Roland P, Theulin A, Carbillon L, Fain O. Intervillites chroniques : étude prospective observationnelle française. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
356
|
Wintenberger-Guillet C, Launay D, Fain O, Kanny G, Bouillet L. L’acide tranexamique comme traitement de fond des angiœdèmes non histaminiques : analyse de l’efficacité et de la tolérance chez 37 patients. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
357
|
Javaud N, Gontier F, Floccard B, Boccon-Gibod I, Amarger S, Martin L, Boumediene A, Coppere B, Ollivier Y, Bouillet L, Adnet F, Fain O. Angiœdèmes bradykiniques : facteurs associés à une hospitalisation en réanimation. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
358
|
Morel N, Levesque K, Hamidou M, Pennaforte J, Piette J, Guettrot-Imbert G, Cohen L, Meyer O, Fain O, Maltret A, Villain E, Costedoat-Chalumeau N. Observatoire français des blocs auriculo-ventriculaires dans le cadre du lupus néonatal : analyse des données maternelles. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
359
|
Khellaf M, Fain O, Viallard J, Cheze S, Hamidou M, Audia S, Schleinitz N, Le Guenno G, Lambotte O, Adoue D, Michel M, Godeau B. Tolérance et efficacité du Rituximab chez les patients adultes atteints de purpura thrombopénique immuologique : résultats après un an de suivi chez 252 patients inclus dans le registre prospectif français PTI-Ritux. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
360
|
Rouet A, Damaj G, Aouba A, Chandesris M, Barète S, Fain O, Durieu I, Grosbois B, Beyne-Rauzy O, Lortholary O, Hermine O, Georgin-Lavialle S. Mastocytose du sujet âgé : à propos de 195 patients dont 80 cas français et 115 cas issus de la littérature. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
361
|
Boccon-Gibod I, Gompel A, Fain O, Launay D, Ollivier Y, Gayet S, Pagnier A, Bouillet L. Angiœdèmes héréditaires à C1-inhibiteur normal avec mutation du facteur XII : étude d’une cohorte française. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
362
|
Cordel H, Cailhol J, Matheron S, Bloch M, Godineau N, Consigny PH, Gros H, Campa P, Bourée P, Fain O, Ralaimazava P, Bouchaud O. Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases. Malar J 2013; 12:399. [PMID: 24200190 PMCID: PMC3831254 DOI: 10.1186/1475-2875-12-399] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2013] [Accepted: 10/30/2013] [Indexed: 11/25/2022] Open
Abstract
Background Each year, thousands of cases of uncomplicated malaria are imported into Europe by travellers. Atovaquone-proguanil (AP) has been one of the first-line regimens used in France for uncomplicated malaria for almost ten years. While AP’s efficacy and tolerance were evaluated in several trials, its use in “real life” conditions has never been described. This study aimed to describe outcome and tolerance after AP treatment in a large cohort of travellers returning from endemic areas. Methods Between September 2002 and January 2007, uncomplicated malaria treated in nine French travel clinics with AP were followed for 30 days after AP initiation. Clinical and biological data were collected at admission and during the follow-up. Results A total of 553 patients were included. Eighty-eight percent of them were born in Africa, and 61.8% were infected in West Africa, whereas 0.5% were infected in Asia. Migrants visiting friends and relatives (VFR) constituted 77.9% of the patients, the remainder (32.1%) were backpackers. Three-hundred and sixty-four patients (66%) fulfilled follow-up at day 7 and 265 (48%) completed the study at day 30. Three patients had treatment failure. One-hundred and seventy-seven adverse drug reactions (ADR) were reported during the follow-up; 115 (77%) of them were digestive ADR. Backpackers were more likely to experiment digestive ADR compared to VFR (OR = 3.8; CI 95% [1.8-8.2]). Twenty patients had to be switched to another regimen due to ADR. Conclusion This study seems to be the largest in terms of number of imported uncomplicated malaria cases treated by AP. The high rate of reported digestive ADR is striking and should be taken into account in the follow-up of patients since it could affect their adherence to the treatment. Beside AP, artemisinin combination therapy (ACT) is now recommended as first-line regimen. A comparison of AP and ACT, in terms of efficacy and tolerance, would be useful.
Collapse
|
363
|
Morel P, Melboucy-Belkhir S, Mekinian A, Javaud N, Fain O. [Herpes simplex encephalitis]. LA REVUE DU PRATICIEN 2013; 63:1196. [PMID: 24422283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
364
|
Gras J, Morin AS, Caux F, Mekinian A, Fain O. [Pemphigoid gestationis]. LA REVUE DU PRATICIEN 2013; 63:1208. [PMID: 24422286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
365
|
Allenbach Y, Rigolet A, Drouot L, Charuel J, Jouen F, Jouen F, Maisonobe T, Dubourg O, Behin A, Eymard B, Laforet P, Stojkovic T, Konepaut I, Konepaut I, Cacoub P, Kieffer P, Fain O, Cosserat J, Morati L, Salort E, Menard D, Antoine J, Tournadre A, Menier VB, Ferrer X, Laroche C, Musset L, Herson S, Boyer O, Benveniste O. P.14.11 Auto-immune necrotizing myopathies with anti-HMGCR antibodies are related to statin-exposure only for a minority of cases. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
366
|
Fain O. [Vitamin C]. LA REVUE DU PRATICIEN 2013; 63:1091-1096. [PMID: 24298827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Vitamin C is a water soluble vitamin which is mainly fresh fruits and vegetables foodborne. Vitamin C deficiency is most often due to a lack of daily amount. Scurvy is characterized by the occurrence of fatigue, myalgia, arthralgia, purpura, bleeding disorders, and later by dental manifestations. Biological signs are nonspecific: anemia, hypocholesterolemia, hypoalbuminemia. Clinical suspicion is confirmed by the decrease in ascorbic acid level (< 2 mg/L). It must be interpreted in light of the acute phase reactants. The treatment is the administration of 1 g of vitamin C per day for 15 days. Vitamin C depletion (ascorbic acid: 2 to 5 mg/L) could induce long-term complications. The recommended dietary allowance of vitamin C protect from these risks.
Collapse
|
367
|
Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. Autoimmun Rev 2013; 12:1143-9. [DOI: 10.1016/j.autrev.2013.06.019] [Citation(s) in RCA: 101] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Accepted: 06/24/2013] [Indexed: 11/24/2022]
|
368
|
Grignano E, Mekinian A, Dubourg O, Dhote R, Fain O. Dramatic response to intravenous immunoglobulins in dysautonomic neurosarcoidosis. J Clin Neurosci 2013; 20:1807-8. [PMID: 24090517 DOI: 10.1016/j.jocn.2013.02.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2012] [Revised: 02/22/2013] [Accepted: 02/25/2013] [Indexed: 11/26/2022]
|
369
|
Mekinian A, Nicaise-Roland P, Chollet-Martin S, Fain O, Crestani B. Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren’s syndrome in the absence of anti-SSA/SSB antibodies by ELISA. Rheumatology (Oxford) 2013; 52:2223-8. [DOI: 10.1093/rheumatology/ket295] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
370
|
Cohen C, Mekinian A, Uzunhan Y, Fauchais AL, Dhote R, Pop G, Eder V, Nunes H, Brillet PY, Valeyre D, Fain O, Soussan M. 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjögren's syndrome. Autoimmun Rev 2013; 12:1109-14. [DOI: 10.1016/j.autrev.2013.06.012] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2013] [Accepted: 06/11/2013] [Indexed: 02/03/2023]
|
371
|
Javaud N, Fain O, Martin L. Angioedèmes bradykiniques. MEDECINE INTENSIVE REANIMATION 2013. [DOI: 10.1007/s13546-013-0696-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
372
|
Roulette M, Konzelmann C, Lordache L, Fain O. [Cerebrospinal fluid fistula]. LA REVUE DU PRATICIEN 2013; 63:899. [PMID: 24167876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|
373
|
Legrand F, Renneville A, MacIntyre E, Mastrilli S, Ackermann F, Cayuela JM, Rousselot P, Schmidt-Tanguy A, Fain O, Michel M, de Jaureguiberry JP, Hatron PY, Cony-Makhoul P, Lefranc D, Sène D, Cottin V, Hamidou M, Lidove O, Baruchel A, Dubucquoi S, Bletry O, Preudhomme C, Capron M, Prin L, Kahn JE. The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. Medicine (Baltimore) 2013; 92:e1-e9. [PMID: 23982058 PMCID: PMC4553979 DOI: 10.1097/md.0b013e3182a71eba] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Imatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic leukemia (F/P CEL), but its optimal dosing, duration, and possibility of discontinuation are still a matter of debate. A retrospective multicenter study was conducted with 44 F/P CEL patients identified in the French Eosinophil Network and treated with imatinib. The most frequently involved systems were skin (57%), spleen (52%), and lung (45%), and eosinophilic heart disease was observed in 15 patients (34%). Complete hematologic response (CHR) was obtained in all patients, and complete molecular response (CMR) in 95% of patients (average initial imatinib dose, 165 mg/d). For 29 patients the imatinib dose was tapered with a maintenance dose of 58 mg/d (±34 mg/d), allowing sustained CHR and CMR. None of the patients developed resistance during a median follow-up of 52.3 months (range, 1.4-97.4 mo). Imatinib was stopped in 11 patients; 6 of the patients subsequently relapsed, but 5 remained in persistent CHR or CMR (range, 9-88 mo). These results confirm that an initial low-dose regimen of imatinib (100 mg/d) followed by a lower maintenance dose can be efficient for obtaining long-term CHR and CMR. Our data also suggest that imatinib can be stopped in some patients without molecular relapse.
Collapse
|
374
|
Bouillet L, Launay D, Fain O, Boccon-Gibod I, Laurent J, Martin L, Montauban V, Finck K, Bouée S, Gompel A, Kanny G. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol 2013; 111:290-4. [PMID: 24054366 DOI: 10.1016/j.anai.2013.07.012] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Revised: 07/10/2013] [Accepted: 07/11/2013] [Indexed: 11/29/2022]
Abstract
BACKGROUND Hereditary angioedema (HAE) is a rare and potentially life-threatening disease. New specific treatments are available. OBJECTIVE To identify patients' features and patients' best therapeutic option. METHODS A 1-year, multicenter, retrospective study was performed. The primary objective was to examine the clinical presentation of HAE. Secondary objectives included patient characteristics, management of HAE over 12 months, and health-related quality of life using the SF-36v2 questionnaire. RESULTS One hundred ninety-three patients were included, and 69.4% were women. In the 12-month period, the mean number of HAE attacks was 7.6. Among the 568 reported attacks, localizations were the abdomen (57.1%), peripheral limbs (42.5%), upper airway (7.9%), and face (6.9%); 31.6% of attacks were severe and occurred statistically more often in women (P < .02). Compared with a population of allergic patients, all age- and sex-adjusted scores were significantly lower in patients with HAE (P < .05) except for the physical component summary. Health-related quality of life negatively correlated with the annual number of attacks and was markedly altered for patients having more than 5 attacks per year (P < .05 for all dimensions). CONCLUSION HAE is a severe disease that places a heavy burden on quality of life.
Collapse
|
375
|
Defendi F, Charignon D, Ghannam A, Baroso R, Csopaki F, Allegret-Cadet M, Ponard D, Favier B, Cichon S, Nicolie B, Fain O, Martin L, Drouet C. Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS One 2013; 8:e70140. [PMID: 23940538 PMCID: PMC3734293 DOI: 10.1371/journal.pone.0070140] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2013] [Accepted: 06/20/2013] [Indexed: 01/11/2023] Open
Abstract
Background The kinins (primarily bradykinin, BK) represent the mediators responsible for local increase of vascular permeability in hereditary angioedema (HAE), HAE I-II associated with alterations of the SERPING1 gene and HAE with normal C1-Inhibitor function (HAE-nC1INH). Besides C1-Inhibitor function and concentration, no biological assay of kinin metabolism is actually available to help physicians for the diagnosis of angioedema (AE). We describe enzymatic tests on the plasma for diagnosis of BK-dependent AE. Methods The plasma amidase assays are performed using the Pro-Phe-Arg-p-nitroanilide peptide substrate to evaluate the spontaneous amidase activity and the proenzyme activation. We analyzed data of 872 patients presenting with BK-dependent AE or BK-unrelated diseases, compared to 303 controls. Anti-high MW kininogen (HK) immunoblot was achieved to confirm HK cleavage in exemplary samples. Reproducibility, repeatability, limit of blank, limit of detection, precision, linearity and receiver operating characteristics (ROC) were used to calculate the diagnostic performance of the assays. Results Spontaneous amidase activity was significantly increased in all BK-dependent AE, associated with the acute phase of disease in HAE-nC1INH, but preserved in BK-unrelated disorders. The increase of the amidase activity was associated to HK proteolysis, indicating its relevance to identify kininogenase activity. The oestrogens, known for precipitating AE episodes, were found as triggers of enzymatic activity. Calculations from ROC curves gave the optimum diagnostic cut-off for women (9.3 nmol⋅min−1⋅mL−1, area under curve [AUC] 92.1%, sensitivity 80.0%, and specificity 90.1%) and for men (6.6 nmol·min−1⋅mL−1, AUC 91.0%, sensitivity 87.0% and specificity 81.2%). Conclusion The amidase assay represents a diagnostic tool to help physicians in the decision to distinguish between BK-related and –unrelated AE.
Collapse
|